Falguni Panchal

Falguni Panchal

Auto-generated profile, based on publicly available information

Falguni Panchal

Department of Clinical Pharmacology, TN Medical College & BYL Nair Charitable Hospital, Mumbai Central, Mumbai, Maharashtra, India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Indian Journal of Medical Research
Verified
Journal Article
Open access
PDF file
UTUrmila Thatte
Urmila Thatte
AKAditi Kulkarni
Aditi Kulkarni
RGRaman Ghungralkar
Raman Ghungralkar
FPFalguni Panchal
Falguni Panchal
SVShamal Vetale
Shamal Vetale
SBSupriya Bhalerao
Supriya Bhalerao
Background & objectives: Basti (medicated enema) is a popular Ayurvedic intervention recommended for obesity. However, there are no data to show whether any physiological or biochemical changes occur following this treatment. This study was conducted to identify the immunological and metabolic changes in obese individuals after a therapeutic course of b0 asti. Methods: Thirty two obese individuals (18 and 60 yr) with a body mass index (BMI) ≥30 kg/m [2] who received a therapeutic course of 16 enemas ( b0 asti) followed by a specific diet and lifestyle regimen for a period of 32 days as their treatment for obesity, were enrolled in the study. Clinical examination, measurement of immune and metabolic markers were done before (S1), immediately after (S2) and 90 days after the completion of therapy (S3). Results: A significant reduction ( P<0.001) in weight, BMI, upper arm and abdominal circumference was seen at S3, along with a decrease in serum interferon (IFN)-γ (P<0.02), interleukin (IL)-6 ( P<0.02) and ferritin (P<0.05) and increase in IgM levels ( P<0.02). Peripheral blood lymphocytes (PBLs) stimulated with anti-CD3 monoclonal antibodies showed significant increase in reactive oxygen species (ROS) generation and calcium flux after Basti. All organ function tests revealed no changes. Interpretation & conclusions: Our study documents that a therapeutic course of Basti modulates immune responses by regulating pro-inflammatory cytokines, immunoglobulins and functional properties of T-cells. These changes are associated with a reduction in the body weight which is maintained even after three months of treatment. The study also documents the safety of Basti procedure.

19 December 2024 in Monaldi Archives for Chest Disease
Verified
Journal Article
Open access
PDF file
RMRenuka Munshi
Renuka Munshi
FPFalguni Panchal
Falguni Panchal
UDUnnati Desai
Unnati Desai
KUKetaki Utpat
Ketaki Utpat
KRKirti Rajoria
Kirti Rajoria
The N-acetyltransferase 2 (NAT2) gene exhibits substantial genetic diversity, leading to distinct acetylator phenotypes among individuals. In this study, we determine NAT2 gene polymorphisms in tuberculosis (TB) patients and analyze serum isoniazid (INH) concentrations across the various genotypes. An observational prospective cohort study involving 217 patients with pulmonary or extrapulmonary TB was carried out. The NAT2 genotypes were identified using real-time polymerase chain reaction technology. INH concentrations at baseline and 2 hours post-dosing were estimated using high-performance liquid chromatography. The association between the acetylator status and INH concentrations was evaluated using odds ratios (OR), and the occurrence of adverse events across the different patient genotypes was also assessed. The genotype frequency of fast, intermediate, and slow acetylators was 7.37%, 39.17%, and 53.46%, respectively, while allele frequency was 27% for fast acetylators and 73% for slow acetylators. All the alleles followed the Hardy-Weinberg equilibrium. Patients with slow acetylator status had significantly increased serum INH concentrations 2 hours post-drug administration, followed by intermediate acetylators, as compared to fast acetylators. 69 (31.8%) patients developed adverse drug reactions post-therapy. Patients with slow acetylator status had the highest (OR: 9.66) risk of developing drug-induced hepatotoxicity, especially those with raised serum INH concentrations (OR: 1.34). Understanding the correlation between genetics and serum antitubercular drug levels in antitubercular drug-induced hepatotoxicity will provide valuable information to the medical community, minimizing the risk of adverse reactions and hospitalizations.

29 May 2025 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
RMRenuka Munshi
Renuka Munshi
FPFalguni Panchal
Falguni Panchal
DKDipti Kumbhar
Dipti Kumbhar
Ayurveda recommends an integrative approach of shodhana & shamana therapy for Obesity management. This study evaluated the safety and efficacy of Navak Guggul and Lekhan Basti, individually and in combination, with respect to anthropometric, biochemical levels and transcriptional profiling of selected candidate genes in obese participants. Single-centre, open-labelled, randomized, comparative, pilot study was conducted following Institutional Ethics Committee approval. 64 obese participants of either gender, aged between 25 and 60 years with BMI 28-32.9 kg/m2 and WHR (Men>0.90 and Women>0.85) were randomly allocated to four groups, each with 16 participants, to receive either Navak Guggul or Lekhan Basti, individually or in combination or no treatment in addition to diet and lifestyle modification. Anthropometric measurements, ayurvedic symptoms severity score, impact of weight on quality of life (IWQOL), biochemical tests and genetic expressions of select genes (UCP2, AD1POR1, FTO, GHRL, Leptin and PPARγ) were assessed at baseline (V1), immediately after therapy (V4) and 2 months post-therapy (V6). 50 participants completed the study. Participants from all groups showed significant reduction in BMI (except Group IV) with significant improvement in the ayurvedic symptoms score. Improvement in the IWQOL score was seen at V4 in all groups with maximal reduction in serum lipids in Groups I and III. Transcriptional profiling revealed increased expression of UCP2, ADIPOR1 and PPARγ genes at V4 and decreased expression of FTO, Ghrelin and Leptin genes compared to V1. Lekhan Basti and combination therapy were beneficial in reducing anthropometric and lipid parameters. Several genes were differentially expressed immediately post-treatment suggesting their role as candidate genes in obesity management.